More MS news articles for July 2001

Transition Therapeutics Inc. Submits Patent Application for Combination Therapy in Multiple Sclerosis

July 18, 2001  9:55am
Source: PR Newswire

TORONTO, Jul 18, 2001 /PRNewswire via COMTEX/ -- Transition Therapeutics Inc. (CDNX:TTH), a Canadian biotechnology company, today announced the Company has submitted a patent application for a combination therapy with interferon for Multiple Sclerosis ("MS") which has shown, in animal models, to be up to 50% more effective than the current interferon-beta therapies alone.

"We are extremely excited about this new discovery," said Dr. Tony Cruz, President & CEO of Transition Therapeutics Inc. "The increased efficacy observed with this combination therapy has the potential to significantly improve the current benefits of interferon therapy in MS patients and also to extend the patent life of existing MS products."

Currently three interferon-based products are the major form of therapy in MS, representing approximately 90% of the MS market or approximately US$1.6 billion in sales worldwide. Sales of the interferon products in MS have increased approximately 20% over the past year.

"The discovery of the combination therapy was made possible by the use of a demyelinating Transgenic Mouse Model recently licensed by Transition Therapeutics Inc.," said Dr. Mario Moscarello, an emeritus scientist at The Hospital for Sick Children Research Institute and a professor emeritus at the University of Toronto. "This model is unique in that it contains most pathologies observed in human disease."

About Transition Therapeutics Inc.

Transition Therapeutics Inc. is a Canadian biotechnology company developing products for Multiple Sclerosis and other large markets in inflammatory and fibrotic diseases. The Company's technology focuses on early stage therapy by inhibiting normal cells from undergoing a conversion to a diseased state. The Company's lead therapeutic program is focused in the treatment of multiple sclerosis with other programs in restenosis, diabetes and obesity.

Transition Therapeutics Inc.'s shares trade on the Canadian Venture Exchange under the ticker symbol, TTH.

To the extent that any statements made in this release contain information that is not historical, these statements are essentially forward- looking. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include: the difficulty of predicting the timing regulatory approvals or outcome of regulatory actions; market and customer acceptance and demand for new pharmaceutical products; ability to market products; the impact of competitive products, services or pricing; timing or success of product development and launch; availability of raw materials; the regulatory environment; fluctuations in operating results; progress of clinical trials; dependence on corporate relationships; government policies or actions; or other risks detailed from time-to-time in the company's filings with Ontario Securities Commission. Forward looking statements can be identified by the use of words such as "expects", "plans", "will", "believes", "estimates", "intends", "may" and other words of similar meaning. Should know or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly update any forward- looking statements.

SOURCE Transition Therapeutics Inc.

CONTACT:          Dr. Tony Cruz, President & CEO, Transition
                  Therapeutics Inc., 415 Yonge Street, Ste. 1103, Toronto, Ontario  M5B 2E7,
                  Ph: 416-260-7770, x.223, Fx: 416-260-2886,
        ; Michael Lincoln, VP of Business
                  Development, Transition Therapeutics Inc., 415 Yonge Street, Ste. 1103,
                  Toronto, Ontario  M5B 2E7, Ph: 416-260-7770, x.225, Fx: 416-260-2886,


Copyright (C) 2001 PR Newswire